Equities
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)3,400.00
  • Today's Change136.00 / 4.17%
  • Shares traded424.77k
  • 1 Year change-14.10%
  • Beta0.5043
Data delayed at least 20 minutes, as of May 19 2022 17:15 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Key statistics

On Thursday, Dechra Pharmaceuticals PLC (DPH:LSE) closed at 3,400.00, 8.56% above its 52-week low of 3,132.00, set on Dec 16, 2020.
52-week range
Today
3,132.00Dec 16 20205,525.00Aug 24 2021
Markit short selling activity
Low
Med
High
Open3,282.00
High3,414.00
Low3,258.00
Bid3,380.00
Offer3,690.00
Previous close3,264.00
Average volume428.54k
Shares outstanding108.39m
Free float106.84m
P/E (TTM)48.74
Market cap3.54bn GBP
EPS (TTM)0.6697
GBP
Annual div (ADY)41.39
GBX
Annual div yield (ADY)1.27%
Div ex-dateMar 03 2022
Div pay-dateApr 07 2022
Data delayed at least 20 minutes, as of May 19 2022 17:15 BST.
More ▼

Investors Chronicle View

The last IC recommendation on Dechra Pharmaceuticals PLC shares was Hold at 3,811.00 on 21 Feb 2022Read the full article

Board of Directors

1/8

Alison Platt, Non-Executive Chairman

2/8

Ian Page, Chief Executive Officer

3/8

Paul Sandland, Chief Financial Officer

4/8

Tony Griffin, Managing Director, Dechra Veterinary Products EU

5/8

Ishbel Macpherson, Senior Independent Non-Executive Director

6/8

Julian Heslop, Non-Executive Director

7/8

Dr Lawson Macartney, Non-Executive Director

8/8

Lisa Bright, Non-Executive Director

Contact

Address:
Dechra Pharmaceuticals PLC
24 Cheshire Avenue
Cheshire Business Park
Lostock Gralam
Northwich
CW9 7UA

T: +44 (0) 1606 814730
F: +44 (0) 1606 814731
E: corporate.enquiries@dechra.com

Financial PR Advisors:
TooleyStreet Communications
Regency Court
68 Caroline Street
Birmingham
B3 3SF

Chief Executive Officer: Ian Page
Chief Financial Officer: Paul Sandland

E: corporate.enquiries@dechra.com

2022 Half-Year Results

An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.